Provided by Tiger Trade Technology Pte. Ltd.

Enveric Biosciences

1.29
-0.0300-2.27%
Post-market: 1.26-0.0294-2.28%19:24 EDT
Volume:107.45K
Turnover:136.49K
Market Cap:4.75M
PE:-0.04
High:1.31
Open:1.30
Low:1.25
Close:1.32
52wk High:17.64
52wk Low:1.25
Shares:3.68M
Float Shares:2.95M
Volume Ratio:0.85
T/O Rate:3.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-29.6654
EPS(LYR):-228.4745
ROE:-183.12%
ROA:-96.72%
PB:0.94
PE(LYR):-0.01

Loading ...

Enveric Biosciences to Feature at B. Riley Securities Summit, Highlighting Neuroplastogen Development

Deep News
·
Jun 30

Enveric Biosciences CEO Joins B. Riley Securities Neuropsychiatry Fireside Chat at Mind, Muscle & Vision Summit

Reuters
·
Jun 29

Enveric Biosciences to attend BIO International Convention

Reuters
·
Jun 16

Enveric Biosciences Expands At-The-Market Equity Offering

TIPRANKS
·
Jun 10

Enveric Biosciences files prospectus supplement to offer additional $2.43 million in shares via ATM agreement

Reuters
·
Jun 10

Enveric Biosciences to attend UBS Virtual CNS Day

Reuters
·
Jun 09

Enveric Biosciences Begins Genotoxicity Testing for EB-003

MT Newswires Live
·
Jun 02

Enveric Biosciences starts IND-enabling genotoxicity studies for lead neuroplastogen EB-003

Reuters
·
Jun 02

Enveric Biosciences Initiates Investigational New Drug (Ind)-Enabling Genotoxicity Studies of Lead Neuroplastogen Candidate Eb-003

THOMSON REUTERS
·
Jun 02

Enveric Biosciences - Initiates Ind-Enabling Genotoxicity Studies for Eb-3

THOMSON REUTERS
·
Jun 02

Enveric Biosciences Shareholders Approve Directors and Reverse Split

TIPRANKS
·
May 30

Enveric says EB-003 shows no phototoxicity risk in preclinical analysis

Reuters
·
May 19

Enveric Biosciences Inc - Eb-003 First Known Compound to Selectively Engage 5-Ht2a and 5-Ht1b Receptors

THOMSON REUTERS
·
May 19

Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis for Lead Neuroplastogen Candidate Eb-003

THOMSON REUTERS
·
May 19

Enveric Biosciences Inc - Eb-003 Shows No Photoreactive Potential in Preclinical Analysis

THOMSON REUTERS
·
May 19

Enveric Biosciences reports Q1 EPS ($1.08) vs. ($14.58) last year

TIPRANKS
·
May 15

Enveric Biosciences Q1 EPS $(1.08) Up From $(14.64) YoY

Benzinga
·
May 15

Enveric net loss narrows to $1.6 million in Q1 FY26; loss per share improves to $1.08

Reuters
·
May 15

Enveric Biosciences Q1 EPS USD -1.08

THOMSON REUTERS
·
May 15

Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

Dow Jones
·
May 15